A leading biotechnology firm has announced the appointment of a new CEO and director of the board.
The Oxford-based company, Immunocore, welcomes Bahija Jallal from AstraZeneca, where she served as president of MedImmune, its global biologics research and development arm.
Significant Experience in Biologics R&D
Bahija Jallal joins Immunocore with considerable experience in the biopharmaceutical sector. At MedImmune, she oversaw the development of several new medicines and significantly expanded its pipeline, from 40 to over 130 molecules targeting diseases such as cancer, respiratory, inflammation, and autoimmunity.
Jallal’s extensive portfolio includes more than 70 peer-reviewed publications and over 15 patents. Her expertise in biologics R&D and immuno-oncology is expected to bolster Immunocore’s efforts as they progress their lead candidate, IMCgp100, towards commercialisation.
Contributions Beyond the Laboratory
Jallal’s influence extends beyond research and development. She serves on the board of Anthem in Indianapolis, Indiana, and the board of trustees of Johns Hopkins University in Baltimore, Maryland.
Additionally, she is a member of the US Government-University-Industry Research Roundtable (GUIRR) of the National Science Foundation and the immediate past president of the board of the Association of Women in Science. In 2017, Jallal was named Woman of the Year by the Healthcare Businesswomen’s Association.
Vision for Immunocore’s Future
Reflecting on her new role, Jallal expressed excitement about leading Immunocore, citing its strong platform and potential in various therapy areas.
She highlighted the company’s success in translating innovative science into clinical applications, with ongoing pivotal trials in uveal melanoma and other disease areas.
Jallal stated, “I am looking forward to helping the company, and its talented employees, bring innovative T cell receptor-based medicines to patients.”
Endorsement from Immunocore’s Chairman
Sir John Bell, chairman of Immunocore, voiced strong support for Jallal’s appointment. He described her as a seasoned pharmaceutical executive with substantial experience in biologics R&D and immuno-oncology.
Bell believes that Jallal is the ideal candidate to lead the company, emphasising her role as a champion for science and diversity.
He acknowledged the contributions of the interim CEO, Andrew Hotchkiss, thanking him for his capable leadership during the transition period.
Immunocore’s Leading Edge in TCR Bispecifics
Immunocore is at the forefront of developing T cell receptor (TCR) bispecifics, a cutting-edge technology with broad therapeutic applications.
Jallal’s appointment comes at a crucial time as the company advances its pipeline of TCR candidates through clinical development.
The firm’s leading candidate, IMCgp100, is on the path towards commercialisation, and Jallal’s expertise is expected to significantly aid this process.
Strategic Vision and Goals
Under Jallal’s leadership, Immunocore aims to further its mission of creating transformative biological therapies.
The company is focusing on expanding its clinical and pre-clinical stage programs across various disease areas, leveraging its robust scientific platform.
Jallal’s strategic vision aligns with Immunocore’s goal to make a significant impact in the biotechnology sector.
A New Chapter for Immunocore
The appointment of Bahija Jallal signifies a pivotal moment for Immunocore.
Her diverse expertise and proven leadership in the biopharmaceutical industry are expected to drive the company’s growth and innovation.
Bahija Jallal’s appointment as CEO marks a new era for Immunocore, with high expectations for the company’s future achievements.
Her extensive experience and strategic vision are poised to steer Immunocore towards greater heights in the biotechnology sector.